West Pharmaceutical Services, Inc. designs and manufactures containment and delivery systems for injectable drugs — the packaging infrastructure the pharmaceutical industry cannot function without. The company operates in two segments: Proprietary Products (~85% of revenue, high-margin) and Contract-Manufactured Products (~15%, lower-margin assembly services).
Proprietary Products encompasses elastomer stoppers and seals, syringe and cartridge components, Crystal Zenith cyclic-olefin polymer vials and syringes (a premium alternative to glass), and self-injection devices (pen injectors, autoinjectors, wearable patches). The business model is fundamentally a razor/razorblade model: WST supplies the reusable tooling platforms, then captures recurring revenue on every vial stopper, pre-filled syringe component, or self-injection device cartridge produced by its pharma and biotech customers. Long-term supply agreements and regulatory lock-in (primary packaging changes require FDA re-validation) create durable switching costs.
As of FY2025, WST generated $3.07B in revenue (+6.3% YoY), $617M in operating income, and $469M in free cash flow. The company is net-cash positive with $791M in cash against $417M in total debt. Approximately 10,600 employees operate globally across Americas, EMEA, and Asia Pacific. Incorporated 1923; IPO 1980.
Investment Thesis
WST is a high-quality healthcare compounder whose moat — regulatory lock-in, proprietary polymer technology, and long-term pharma supply contracts — is among the most defensible in medical supplies. The stock is recovering from a 2022–2024 destocking cycle in which COVID-era vial production pulled forward demand, leaving customers with excess inventory that suppressed orders for 18+ months.
Structural tailwinds are re-emerging: (1) GLP-1 self-injection device demand — the explosive growth of GLP-1 agonists (semaglutide, tirzepatide) requires billions of autoinjector and pen-injector components, a direct WST Proprietary Products strength; (2) EU Annex 1 sterile manufacturing regulations drive pharma customers toward higher-value WST components (elastomer seals + Crystal Zenith) and away from in-house glass; (3) High-Value Product (HVP) mix shift — WST's highest-margin items (coated stoppers, Crystal Zenith, self-injection platforms) are growing faster than base elastomers, expanding segment margins structurally.
Key risk: At 47.5x TTM P/E and 31x EV/EBITDA, the stock prices near-perfection. Consensus PTs now sit slightly below the current price. Volume recovery from post-COVID destocking must materialize; any guidance miss resets a premium multiple from elevated levels. The May 2026 cyberattack (operations now fully restored) adds a near-term execution overhang.
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.83B | $2.89B | $2.95B | $2.89B | $3.07B |
| Revenue Growth | — | +1.9% | +2.3% | −2.0% | +6.3% |
| Gross Profit | $1.17B | $1.14B | $1.13B | $1.00B | $1.10B |
| Gross Margin | 41.5% | 39.5% | 38.4% | 34.6% | 35.9% |
| Operating Income | $759M | $764M | $711M | $595M | $617M |
| Operating Margin | 26.8% | 26.5% | 24.1% | 20.6% | 20.1% |
| EBITDA | $880M | $808M | $844M | $744M | $724M |
| EBITDA Margin | 31.1% | 28.0% | 28.6% | 25.7% | 23.5% |
| Net Income | $662M | $586M | $593M | $493M | $494M |
| Net Margin | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% |
| EPS (Diluted) | $8.67 | $7.73 | $7.88 | $6.69 | $6.80 |
| R&D Expense | $52.8M | $58.5M | $68.4M | $69.1M | $74.3M |
| SG&A + R&D % Rev | 14.6% | 13.1% | 14.3% | 14.1% | 15.2% |
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $763M | $894M | $854M | $485M | $791M |
| Total Current Assets | $1.74B | $1.92B | $1.94B | $1.54B | $1.98B |
| PP&E, net | $1.13B | $1.26B | $1.51B | $1.69B | — |
| Total Assets | $3.31B | $3.62B | $3.83B | $3.64B | $4.27B |
| Total Debt | $325M | $318M | $309M | $305M | $417M |
| Net Cash (Debt) | $437M | $576M | $545M | $179M | $375M |
| Stockholders' Equity | $2.34B | $2.68B | $2.88B | $2.68B | $3.18B |
| Current Ratio | 2.93x | 3.70x | 2.88x | 2.79x | 3.02x |
| Debt/Equity | 0.14x | 0.12x | 0.11x | 0.11x | 0.13x |
| Goodwill | $110M | $107M | $109M | $106M | $110M |
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $584M | $724M | $777M | $653M | $755M |
| Capital Expenditures | ($253M) | ($285M) | ($362M) | ($377M) | ($286M) |
| Free Cash Flow | $331M | $439M | $415M | $276M | $469M |
| FCF Margin | 11.7% | 15.2% | 14.1% | 9.6% | 15.3% |
| Share Repurchases | ($152M) | ($222M) | ($451M) | ($567M) | ($134M) |
| Dividends Paid | ($51M) | ($54M) | ($57M) | ($59M) | ($61M) |
| D&A | $122M | $121M | $137M | $155M | $169M |
| Stock-Based Comp | $38M | $24M | $23M | $19M | $24M |
| Capex % of Revenue | 9.0% | 9.9% | 12.3% | 13.0% | 9.3% |
| Multiple | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 (current $) |
|---|---|---|---|---|---|
| P/E (TTM) | 52.7x | 29.9x | 44.1x | 48.5x | 47.5x |
| EV/EBITDA | 39.2x | 21.0x | 30.3x | 31.9x | 31.0x |
| P/Sales | 12.3x | 6.1x | 8.9x | 8.3x | 7.4x |
| P/FCF | 105.5x | 39.8x | 63.1x | 86.5x | 48.6x |
| P/Book | 14.9x | 6.5x | 9.1x | 8.9x | 7.4x |
| EV/Sales | 12.2x | 5.9x | 8.7x | 8.2x | 7.3x |
| Dividend Yield | 0.15% | 0.31% | 0.22% | 0.25% | 0.27% |
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Return on Equity | 28.3% | 21.8% | 20.6% | 18.4% | 15.5% |
| Return on Assets | 20.0% | 16.2% | 15.5% | 13.5% | 11.6% |
| Return on Invested Capital | 23.5% | 20.5% | 17.8% | 15.7% | 13.6% |
| Return on Capital Employed | 27.9% | 24.6% | 22.5% | 19.2% | 17.1% |
| Asset Turnover | 0.85x | 0.80x | 0.77x | 0.79x | 0.72x |
| Inventory Turnover | 4.4x | 4.2x | 4.2x | 5.0x | 4.4x |
| Days Sales Outstanding | 63.1 | 64.2 | 63.3 | 69.7 | 68.2 |
| Interest Coverage Ratio | 89.3x | 100.5x | 80.8x | 205.0x | 1,029x |
| FCF Conversion (FCF/NI) | 50.0% | 75.0% | 69.9% | 56.1% | 94.9% |
| Metric | FY2027E | FY2028E | FY2029E |
|---|---|---|---|
| Revenue (avg) | $3.53B | $3.77B | $4.05B |
| Rev Growth (implied) | +14.9% | +6.8% | +7.6% |
| EBITDA (avg) | $967M | $1,032M | $1,110M |
| Net Income (avg) | $690M | $771M | $892M |
| EPS (avg, diluted) | $9.57 | $10.73 | $12.26 |
| Fwd P/E (at $322.81) | 33.7x | 30.1x | 26.3x |
| # Analysts (Rev / EPS) | 11 / 9 | 8 / 2 | 7 / 1 |
| Date | Name | Title | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-12 | Campbell Shane Alden | SVP, Proprietary Segment | RSU Vest | 769.6 | — |
| 2026-05-12 | Campbell Shane Alden | SVP, Proprietary Segment | Tax Withhold | 219.3 | $312.07 |
| 2026-05-04 | Paolo Pucci | Director | Award | 791 | — |
| 2026-05-04 | Douglas A Michels | Director | Award | 791 | — |
| 2026-05-04 | Stephen H Lockhart | Director | Award | 791 | — |
| 2026-05-04 | Myla Lai-Goldman | Director | Award | 791 | — |
| 2026-05-04 | Deborah L Keller | Director | Award | 791 | — |
| 2026-05-04 | Multiple Directors (5) | Directors | Award | 3,955 | — |
- GLP-1 supercycle accelerates. Autoinjector and pen-injector component volumes tied to GLP-1 agonist prescriptions (semaglutide, tirzepatide) scale toward multi-billion unit demand annually. WST is uniquely positioned as a validated supplier for self-injection drug delivery.
- HVP mix re-expands margins. High-Value Products (coated stoppers, Crystal Zenith polymer vials/syringes, wearable injectors) carry gross margins materially above the corporate average. A return to the peak 41%+ gross margins of FY2021 would generate $1.3B+ in gross profit on consensus FY2028 revenue.
- EU Annex 1 regulatory tailwind. Revised EU sterile manufacturing regulations push pharma customers to upgrade primary packaging — a sustained multi-year demand driver for WST's elastomer and Crystal Zenith products.
- Net cash fortress + consistent buybacks. $375M net cash position and $755M operating cash flow support continued share count reduction (−3.6M shares FY2021–FY2025 diluted). Multiple expansion on higher EPS base reaches $380–$400+ by late 2026.
- Premium multiple, modest near-term upside. At 47.5x TTM P/E and 31x EV/EBITDA, consensus PTs imply negative returns from current levels. Any demand shortfall or guidance trim compresses a high starting multiple — a double-hit on the stock.
- Post-COVID vial destocking persists. The 2020–2022 COVID vaccine manufacturing surge created massive elastomeric stopper and closure inventory at pharma customers. Full destocking normalization took longer than expected; any renewed inventory build delays volume recovery.
- Customer concentration and generic softness. Major pharma/biotech customers each represent outsized order volume. Generic drug softness reduces demand for commodity closures, pressuring the Contract-Manufactured Products segment and diluting HVP mix.
- Cyberattack execution overhang. The May 2026 ransomware event (operations fully restored per May 20 disclosure) introduces near-term uncertainty around customer delivery commitments, insurance costs, and potential future vulnerability.
This report was generated using FMP financial data as of June 1, 2026. This is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.